Chemical formula: C₈H₈F₃N₃O₄S₂ Molecular mass: 331.292 g/mol PubChem compound: 3647
HCTZ did not cause reproductive toxicity when administered to pregnant mice or rats.
Hydroflumethiazide does cross the placental barrier. Thiazides may decrease placental perfusion, increase uterine inertia and inhibit labour.
There is limited experience with hydroflumethiazide during pregnancy, especially during the first trimester. Based on the pharmacological mechanism of action of thiazides their use during the second and third trimester may compromise placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.
Hydroflumethiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.
Hydroflumethiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.
Hydroflumethiazide is excreted in human milk in small amounts. Hydroflumethiazide, when given at high doses, can cause intense diuresis, which can in turn inhibit milk production. Its use during breast feeding is not recommended. If it is used during breast feeding, doses should be kept as low as possible.
A different thiazide, hydrochlorothiazide (HCTZ), when administered to mice and rats did not affect fertility.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
